Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib

Sunitinib is an anti-angiogenic receptor tyrosine kinase inhibitor used to treat advanced metastatic renal cell carcinoma and other types of cancer. Sutent is effective in only approximately 70% of clear cell renal cell carcinoma (CCRCC) patients, has significant adverse side effects and no method i...

Descripción completa

Detalles Bibliográficos
Autores principales: Siraj, Muhammad A, Pichon, Christophe, Radu, Aurelian, Ghinea, Nicolae
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822971/
https://www.ncbi.nlm.nih.gov/pubmed/22129368
http://dx.doi.org/10.1111/j.1582-4934.2011.01495.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822971/
https://www.ncbi.nlm.nih.gov/pubmed/22129368
http://dx.doi.org/10.1111/j.1582-4934.2011.01495.x

Ejemplares similares